- Previous Close
3.0400 - Open
3.1500 - Bid --
- Ask --
- Day's Range
3.0600 - 3.2087 - 52 Week Range
2.7300 - 7.8700 - Volume
19,111 - Avg. Volume
100,749 - Market Cap (intraday)
20.921M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
0.80 - EPS (TTM)
3.9200 - Earnings Date Sep 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 16, 2023
- 1y Target Est
6.00
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
www.meipharma.comRecent News: MEIP
View MorePerformance Overview: MEIP
Trailing total returns as of 9/19/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MEIP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MEIP
View MoreValuation Measures
Market Cap
21.05M
Enterprise Value
-23.83M
Trailing P/E
0.81
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.32
Price/Book (mrq)
0.41
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
39.18%
Return on Assets (ttm)
12.40%
Return on Equity (ttm)
61.26%
Revenue (ttm)
66.75M
Net Income Avi to Common (ttm)
26.16M
Diluted EPS (ttm)
3.9200
Balance Sheet and Cash Flow
Total Cash (mrq)
56.55M
Total Debt/Equity (mrq)
22.86%
Levered Free Cash Flow (ttm)
7.19M
Research Analysis: MEIP
View MoreCompany Insights: MEIP
MEIP does not have Company Insights